END TB – THE NEW WHO STRATEGY IN THE SDG ERA* , AND THE CONTRIBUTIONS FROM THE RUSSIAN FEDERATION
https://doi.org/10.21292/2075-1230-2016-94-11-7-15
Abstract
About the Authors
M. C. RaviglioneSwitzerland
Director,
WHO Global TB Programme 20, Avenue Appia, 1211 Geneva 27
A. A. Korobitsyn
Switzerland
Technical Officer,
WHO Global TB Programme 20, Avenue Appia, 1211 Geneva 27
References
1. Global Tuberculosis Report 2016. WHO/HTM/TB/2016.13. Geneva, World Health Organization, 2016.
2. M. Raviglione. Ending TB – Global situation and a new strategy in the SDG era. Presentation at the 7th Conference of the Union European Region. 3. The Global Fund. http://www.theglobalfund.org/en/tuberculosis/
3. Uplekar M. Public-private mix for tuberculosis care and prevention. What progress? What prospects? Int. J. Tuberc. Lung Dis., 2016, vol. 20(11), pp. 1424-1429.
4. UNAIDS Fact sheet, 2016. http://www.unaids.org/en/resources/fact-sheet 6. WHO policy on collaborative TB/HIV activities: guidelines for national programmes and other stakeholders. WHO/ HTM/TB/2012.1. Geneva, World Health Organization, 2012.
5. Tanimura T., Jaramillo E., Weil D., Raviglione M., Lönnroth K. Financial burden for tuberculosis patients in low- and middle-income countries: a systematic review. Eur. Respir. J ., 2014, vol. 43, pp. 1763-1775.
6. The End TB strategy. Global strategy and targets for tuberculosis prevention, care and control after 2015. The official text approved by the Sixty seventh World Health Assembly, May 2014.
7. Implementing The End TB strategy: The Essentials. WHO/HTM/TB/2015.31. Geneva, World Health Organization, 2015.
8. Grzybowski S., Styblo K., Dorken E. Tuberculosis in Eskimos. Tubercle, 1976, suppl. 57, pp 1-58.
9. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children. Policy update. WHO/HTM/TB/2013.16, Geneva, World Health Organization, 2013.
10. Implementing tuberculosis diagnostics. Policy framework. WHO/HTM/TB/2015.11. Geneva, World Health Organization, 2015.
11. The use of molecular line probe assays for the detection of resistance to isoniazid and rifampicin. Policy guidance. 2016 update. WHO/HTM/TB/2016.12. Geneva, World Health Organization, 2016.
12. The use of molecular line probe assays for the detection of resistance to second-line anti-TB drugs. Policy guidance. WHO/HTM/TB/2016.07. Geneva, World Health Organization, 2016.
13. WHO treatment guidelines for drug-resistant tuberculosis. 2016 update. WHO/HTM/TB/2016.04 Geneva, World Health Organization, 2016.
14. Getahun H., Matteelli A., Abubakar I., Aziz M.A., Baddeley A., Barreira D. et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur. Respir. J., 2015, Dec., vol. 46(6), pp. 1563-76.
15. Guidelines on the management of latent tuberculosis infection. WHO/HTM/TB/2015.01. Geneva, World Health Organization, 2015.
16. Lönnroth K., Jaramillo E., Williams B.G., Dye C., Raviglione M. Drivers of tuberculosis epidemics: The role of risk factors and social determinants. Social Science & Medicine, vol. 68, 2009, pp. 2240-2246.
17. Lönnroth K., Raviglione M. The WHO’s new End TB Strategy in the post-2015 era of the sustainable Development Goals. Trans. R. Soc. Trop. Med., Hyg., 2016, vol. 110, pp.148–150.
18. Siroka A., Ponce N.A., Lönnroth K. Association between spending on social protection and tuberculosis burden: a global analysis. Lancet Infect. Dis., 2016, vol. 16, pp. 473-79.
19. Boccia D., Pedrazzoli D., Wingfield T., Jaramillo E., Lönnroth K., Lewis J. et all. Towards cash transfer interventions for tuberculosis prevention, care and control: key operational challenges and research priorities. BMC Infectious Diseases, 2016, vol.16, pp. 307.
20. A WHO/The Union Monograph on TB and Tobacco Control. Joining efforts to control two related epidemics. WHO/HTM/TB/2007.390. Geneva, World Health Organization, 2007.
21. Creswell J., Raviglione M., Ottmani S., Migliori G.B., Uplekar M., Blanc L., Sotgiu G., Lönnroth K. Tuberculosis and noncommunicable diseases: neglected links and missed opportunities. Eur. Respir. J., 2011, vol. 37, pp. 1269-1282.
22. Lönnroth K., Williams B.G., Jaramillo E., Stadlin S., Dye C. Alcohol use as a risk factor for tuberculosis – a systematic review. BMC Public Health, 2008, vol. 8, pp. 289.
23. Lönnroth K., Roglic G., Harries A.D. Improving tuberculosis prevention and care through addressing the global diabetes epidemic: from evidence to policy and practice. Lancet Diabetes Endocrinol., 2014, vol. 2, pp. 730-39.
24. Precision Medicine Initiative. NIH-USA. https://www.nih.gov/precision-medicine-initiative-cohort-program
25. Digital health for the End TB Strategy - an agenda for action. WHO/HTM/TB/2015.21. Geneva, World Health Organization, 2015.
26. Falzon D., Timimi H., Kurosinski P., Migliori G.B., Van Gemert W., Denkinger C. et al. Digital Health for the End TB Strategy: developing priority products and making them work. Eur. Respir. J., 2016, pp. 29-45.
27. Falzon D., Raviglione M. The Internet of Things to come: digital technologies and the End TB Strategy. BMJ, 2016, DOI: 10.1136/bmjgh-2016-000038.
28. GLI guide to the connectivity solutions, Geneva, 2016.
Review
For citations:
Raviglione M.C., Korobitsyn A.A. END TB – THE NEW WHO STRATEGY IN THE SDG ERA* , AND THE CONTRIBUTIONS FROM THE RUSSIAN FEDERATION. Tuberculosis and Lung Diseases. 2016;94(11):7-15. (In Russ.) https://doi.org/10.21292/2075-1230-2016-94-11-7-15